Abstract:Background: Proline-rich transmembrane protein 2 (PRRT2) plays an important role in the central nervous system and mutations in the gene are implicated in a variety of neurological disorders. This study aimed to summarize the clinical characteristics and gene expression analysis of neurological diseases related to the PRRT2 gene and explore the clinical characteristics, therapeutic effects, and possible pathogenic mechanisms of related diseases. Methods: We enrolled 10 children with PRRT2 mutation-related neurological diseases who visited the Children's Hospital affiliated with the Shanghai Jiaotong University School of Medicine/Shanghai Children's Hospital between May 2017 and February 2022. Video electroencephalography (VEEG), cranial imaging, treatment regimens, gene results, and gene expression were analyzed. Genetic testing involved targeted sequencing or whole-exome genome sequencing (WES). We further analyzed the expression and mutation conservation of PRRT2 and synaptosome-associated protein 25 (SNAP25) in blood samples using quantitative polymerase chain reaction (qPCR) and predicted the protein structure. Summary analysis of the reported gene maps and domains was also performed. Results: Ten children with PRRT2 gene mutations were analyzed, and 4 mutations were identified, consisting of 2 new (c.518A > C, p.Glu173 Ala; c.879 + 112G > A, p.?) and two known (c. 649 dup, p. Arg217Profs * 8; c. 649 del, p. Arg217Glufs * 12) mutations. Among these mutations, one was de novo (P6), and three could not be determined because one parent refused genetic testing. The clinical phenotypes were paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy (BFIE), epilepsy, infantile spasms, and intellectual disability. The qPCR results showed that PRRT2 gene expression levels were significantly lower in children and parent carriers than the control group. The SNAP25 gene expression level of affected children was significantly lower ( P ≤ 0.001) than that of the control group. The mutation sites reported in this study are highly conserved in different species. Among the various drugs used, oxcarbazepine and sodium valproate were the most effective. All 10 children had a good disease prognosis, and 8 were completely controlled with no recurrence, whereas 2 had less severe and fewer seizures. Conclusion: Mutation of PRRT2 led to a significant decrease in its protein expression level and that of SNAP25, suggesting that the mutant protein may lead to the loss of its function and that of related proteins. This mutation site is highly conserved in most species, and there was no significant correlation between specific PRRT2 genotypes and clinical phenotypes. Asymptomatic carriers also have decreased gene expression levels, suggesting that more factors are involved.

[Clinical and genetic analysis of two children with TANC2 gene variants and a literature review]

Truncating mutation in TANC2 in a Chinese boy associated with Lennox-Gastaut syndrome: a case report

Clinical characteristics and genetics of ten Chinese children with PRRT2-associated neurological diseases

A Novel Pathogenic Variant in CNOT3 Causing Neurodevelopmental Delay and Epilepsy

Disruptive Mutations in TANC2 Define a Neurodevelopmental Syndrome Associated with Psychiatric Disorders

Novel variants of SYNGAP1 associated epileptic encephalopathy: two cases report and literature review

Case Report: Causative De Novo Variants of KCNT2 for Developmental and Epileptic Encephalopathy

Exploring the clinical spectrum of CNTNAP2-related neurodevelopmental disorders: A case series and a literature appraisal

The Genotype–phenotype Correlations of the CACNA1A-related Neurodevelopmental Disorders: a Small Case Series and Literature Reviews

Identification of a novel KCNT2 variant in a family with developmental and epileptic encephalopathies: a case report and literature review

Case report: A novel TLK2 variant with a neuropsychiatric phenotype from a Chinese family

Clinical and genetic characterization of patients segregating variants in KPTN, MINPP1, NGLY1, AP4B1, and SON underlying neurodevelopmental disorders: Genetic and phenotypic expansion

[Clinical characteristics and genetic analysis of two children with X-linked Centronuclear myopathy due to variants of MTM1 gene]

[Correlation of early neurodevelopmental features of children with SYNGAP1 variants and their genotypes]

Familial and genetic association with neurodevelopmental disorders caused by a heterozygous variant in the SRRM2 gene

Genetic Analysis of Neurodevelopmental Disorders in Children

Possible Catch-Up Developmental Trajectories for Children with Mild Developmental Delay Caused by NAA15 Pathogenic Variants

Case Report: De Novo Variants of KMT2E Cause O'Donnell-Luria-Rodan Syndrome: Additional Cases and Literature Review.

Familial SYN1 Pathogenic Mutations Related Neurodevelopmental Disorders in Asian Pediatric Patients

A Novel Variant of the CHD2 Gene Associated With Developmental Delay and Myoclonic Epilepsy

Two Novel Heterozygous Truncating Variants in NR4A2 Identified in Patients with Neurodevelopmental Disorder and Brief Literature Review